Hormonal
GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide) reduce major adverse cardiovascular events (MACE) and promote histological resolution of MASH in patients with T2D and MASLD.
If you have Type 2 Diabetes and fatty liver disease, ask your doctor about GLP-1 receptor agonists (like semaglutide or liraglutide). These drugs are proven to significantly lower your risk of heart attacks and strokes, and they can even reverse liver inflammation (MASH) in some patients. They are a key part of modern care for this condition.
The LEADER trial showed that liraglutide reduced the risk of major adverse cardiovascular events by 13%... The phase 2 LEAN trial showed that liraglutide promoted histological resolution of metabolic dysfunction-associated steatohepatitis (MASH) in patients with biopsy-proven disease.
Why this rating
Supported by large CV outcome trials (LEADER, SUSTAIN-6, REWIND) and phase 2 histology trials (LEAN), though large-scale fibrosis regression data is still needed.
Source
Cardiovascular Health in the Shadow of Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: An Emerging Paradigm
Alfredo Caturano et al. · Reviews in Cardiovascular Medicine · 2025
DOI 10.31083/rcm43143
More from this paper
- SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) significantly reduce cardiovascular mortality and heart failure hospitalization in type 2 diabetes patients, while also reducing liver fat content and improving liver enzymes in those with MASLD.Good
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, achieves superior weight loss and hepatic steatosis reduction compared to semaglutide, with preliminary cardiovascular non-inferiority data.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →